Shield Therapeutics plc (STX) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.303x

Based on the latest financial reports, Shield Therapeutics plc (STX) has a cash flow conversion efficiency ratio of 0.303x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-4.49 Million ≈ $-546.85 USD) by net assets (GBX-14.86 Million ≈ $-1.81K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See STX equity financing ratio to measure how much of total assets are equity-financed.

Shield Therapeutics plc - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how Shield Therapeutics plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Shield Therapeutics plc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.

Shield Therapeutics plc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Shield Therapeutics plc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
BlackRock Income and Growth Investment Trust plc LSE:BRIG	0.017x
Trade & Value AG HM:TAV	N/A
PCI-PAL PLC LSE:PCIP	-0.753x
DETALION GAMES SA ZY -10 F:9XJ	0.001x
Cora Gold Limited LSE:CORA	-0.013x
Upsellon Brands Holdings Ltd TA:CHR	0.180x
T-Bull S.A WAR:TBL	-0.195x
CORELENS S.A. ZY -10 F:9GK	-0.301x

Annual Cash Flow Conversion Efficiency for Shield Therapeutics plc (2014–2024)

The table below shows the annual cash flow conversion efficiency of Shield Therapeutics plc from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see STX market cap overview.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	GBX-1.05 Million ≈ $-127.95	GBX-7.01 Million ≈ $-852.49	6.663x	+500.42%
2023-12-31	GBX22.31 Million ≈ $2.71K	GBX-37.13 Million ≈ $-4.52K	-1.664x	+50.51%
2022-12-31	GBX5.43 Million ≈ $660.31	GBX-18.25 Million ≈ $-2.22K	-3.362x	-724.25%
2021-12-31	GBX41.03 Million ≈ $4.99K	GBX-16.74 Million ≈ $-2.04K	-0.408x	-782.15%
2020-12-31	GBX30.28 Million ≈ $3.68K	GBX-1.40 Million ≈ $-170.34	-0.046x	+63.44%
2019-12-31	GBX32.15 Million ≈ $3.91K	GBX-4.07 Million ≈ $-494.71	-0.126x	-2773.01%
2018-12-31	GBX40.43 Million ≈ $4.92K	GBX-178.00K ≈ $-21.66	-0.004x	+98.88%
2017-12-31	GBX41.21 Million ≈ $5.01K	GBX-16.15 Million ≈ $-1.97K	-0.392x	-84.95%
2016-12-31	GBX48.40 Million ≈ $5.89K	GBX-10.26 Million ≈ $-1.25K	-0.212x	-194.45%
2015-12-31	GBX-18.64 Million ≈ $-2.27K	GBX-4.18 Million ≈ $-508.95	0.224x	+22.79%
2014-12-31	GBX-18.28 Million ≈ $-2.22K	GBX-3.34 Million ≈ $-406.50	0.183x	--

About Shield Therapeutics plc

LSE:STX UK Drug Manufacturers - Specialty & Generic

Market Cap

$519.78K

GBX4.27 Billion GBX

Market Cap Rank

#30902 Global

#917 in UK

Share Price

GBX4.00

Change (1 day)

+8.11%

52-Week Range

GBX3.70 - GBX12.20

All Time High

GBX185.02